Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection

View ORCID ProfilePablo Garcia-Valtanen, View ORCID ProfileChristopher M. Hope, View ORCID ProfileMakutiro G. Masavuli, View ORCID ProfileArthur Eng Lip Yeow, View ORCID ProfileHarikrishnan Balachandran, View ORCID ProfileZelalem A. Mekonnen, View ORCID ProfileZahraa Al-Delfi, View ORCID ProfileArunasingam Abayasingam, View ORCID ProfileDavid Agapiou, View ORCID ProfileAlberto Ospina Stella, View ORCID ProfileAnupriya Aggarwal, View ORCID ProfileJason Gummow, Catherine Ferguson, Stephanie O’Connor, Erin M. McCartney, View ORCID ProfileDavid J. Lynn, View ORCID ProfileGuy Maddern, View ORCID ProfileEric J Gowans, Benjamin AJ Reddi, David Shaw, Chuan Kok-Lim, View ORCID ProfileStuart G Turville, View ORCID ProfileMichael R Beard, View ORCID ProfileDaniela Weiskopf, View ORCID ProfileAlessandro Sette, View ORCID ProfileRowena A. Bull, View ORCID ProfileSimon C. Barry, View ORCID ProfileBranka Grubor-Bauk
doi: https://doi.org/10.1101/2021.11.08.21266035
Pablo Garcia-Valtanen
1Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pablo Garcia-Valtanen
Christopher M. Hope
2Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia
3Women’s and Children’s Health Network, North Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher M. Hope
Makutiro G. Masavuli
1Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Makutiro G. Masavuli
Arthur Eng Lip Yeow
1Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Arthur Eng Lip Yeow
Harikrishnan Balachandran
4School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harikrishnan Balachandran
Zelalem A. Mekonnen
1Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zelalem A. Mekonnen
Zahraa Al-Delfi
1Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zahraa Al-Delfi
Arunasingam Abayasingam
4School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Arunasingam Abayasingam
David Agapiou
4School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Agapiou
Alberto Ospina Stella
5The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alberto Ospina Stella
Anupriya Aggarwal
5The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anupriya Aggarwal
Jason Gummow
6Gene Silencing and Expression Core Facility, Adelaide Health and Medical Sciences, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason Gummow
Catherine Ferguson
7Infectious Diseases Department, Royal Adelaide Hospital, Central Adelaide Local Health Network Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie O’Connor
8Intensive Care Unit, Royal Adelaide Hospital, Central Adelaide Local Health Network and Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin M. McCartney
7Infectious Diseases Department, Royal Adelaide Hospital, Central Adelaide Local Health Network Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Lynn
9Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia
10Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David J. Lynn
Guy Maddern
11Discipline of Surgery, The University of Adelaide, Adelaide, SA 5000, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guy Maddern
Eric J Gowans
1Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric J Gowans
Benjamin AJ Reddi
8Intensive Care Unit, Royal Adelaide Hospital, Central Adelaide Local Health Network and Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Shaw
7Infectious Diseases Department, Royal Adelaide Hospital, Central Adelaide Local Health Network Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chuan Kok-Lim
6Gene Silencing and Expression Core Facility, Adelaide Health and Medical Sciences, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia
12Microbiology and Infectious Diseases Department, SA Pathology, Adelaide, SA, Australia
13Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart G Turville
5The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stuart G Turville
Michael R Beard
13Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael R Beard
Daniela Weiskopf
14Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniela Weiskopf
Alessandro Sette
14Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA
15Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alessandro Sette
Rowena A. Bull
4School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rowena A. Bull
  • For correspondence: branka.grubor@adelaide.edu.au simon.barry@adelaide.edu.au r.bull@unsw.edu.au
Simon C. Barry
2Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia
3Women’s and Children’s Health Network, North Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simon C. Barry
  • For correspondence: branka.grubor@adelaide.edu.au simon.barry@adelaide.edu.au r.bull@unsw.edu.au
Branka Grubor-Bauk
1Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide, SA, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Branka Grubor-Bauk
  • For correspondence: branka.grubor@adelaide.edu.au simon.barry@adelaide.edu.au r.bull@unsw.edu.au
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The duration and magnitude of SARS-CoV-2 immunity after infection, especially with regard to the emergence of new variants of concern (VoC), remains unclear. Here, immune memory to primary infection and immunity to VoC was assessed in mild-COVID-19 convalescents one year after infection and in the absence of viral re-exposure or COVID-19 vaccination.

Methods Serum and PBMC were collected from mild-COVID-19 convalescents at ∼6 and 12 months after a COVID-19 positive PCR (n=43) and from healthy SARS-CoV-2-seronegative controls (n=15-40). Serum titers of RBD and Spike-specific Ig were quantified by ELISA. Virus neutralisation was assessed against homologous, pseudotyped virus and homologous and VoC live viruses. Frequencies of Spike and RBD-specific memory B cells were quantified by flow cytometry. Magnitude of memory T cell responses was quantified and phenotyped by activation-induced marker assay, while T cell functionality was assessed by intracellular cytokine staining using peptides specific to homologous Spike virus antigen and four VoC Spike antigens.

Findings At 12 months after mild-COVID-19, >90% of convalescents remained seropositive for RBD-IgG and 88.9% had circulating RBD-specific memory B cells. Despite this, only 51.2% convalescents had serum neutralising activity against homologous live-SARS-CoV-2 virus, which decreased to 44.2% when tested against live B.1.1.7, 4.6% against B.1.351, 11.6% against P.1 and 16.2%, against B.1.617.2 VoC. Spike and non-Spike-specific T cells were detected in >50% of convalescents with frequency values higher for Spike antigen (95% CI, 0.29-0.68% in CD4+ and 0.11-0.35% in CD8+ T cells), compared to non-Spike antigens. Despite the high prevalence and maintenance of Spike-specific T cells in Spike ‘high-responder’ convalescents at 12 months, T cell functionality, measured by cytokine expression after stimulation with Spike epitopes corresponding to VoC was severely affected.

Interpretations SARS-CoV-2 immunity is retained in a significant proportion of mild COVID-19 convalescents 12 months post-infection in the absence of re-exposure to the virus. Despite this, changes in the amino acid sequence of the Spike antigen that are present in current VoC result in virus evasion of neutralising antibodies, as well as evasion of functional T cell responses.

Funding This work was funded by project grants from The Hospital Research Foundation and Women’s and Children’s Hospital Foundation, Adelaide, Australia. MGM is THRF Early Career Fellow. BGB is THRF Mid-Career Fellow. This project has been supported partly with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and Contract No. 75N9301900065 to A.S, D.W.

Evidence before this study We regularly searched on PubMed and Google Scholar in June-October 2021 using individual or combinations of the terms “long-term immunity”, “SARS-CoV-2”, “antigenic breadth”, “variant of concern” and “COVID-19”. We found studies that had assessed immune correlates at multipe time points after COVID-19 disease onset in convalescents, but not the antigenic breadth of T cells and antibodies and not in relation to VoC. Other immune studies in virus naive vaccinees, or vaccinated convalescents evaluated VoC-specific immunity, but not in convalescents that have not been vaccinated. In summary, we could not find long-term studies providing and in-depth evaluation of functionality of humoral and cell-mediated immunity, combined with addressing the adaptability of these immune players to VoC.

Added value of this study The window of opportunity to conduct studies in COVID-19 convalescents (i.e. natural immunity to SARS-CoV-2) is closing due to mass vaccination programs. Here, in a cohort of unvaccinated mild-COVID-19 convalescents, we conducted a comprehensive, longitudinal, long-term immune study, which included functional assays to assess immune fitness against antigenically different VoC. Importantly, the cohort resided in a SARS-CoV-2-free community for the duration of the study with no subsequent re-exposure or infection. Our findings reveal a deeply weakened humoral response and functional vulnerability of T cell responses to VoC Spike antigens.

Implications of all the available evidence This study provides a valuable snapshot of the quality of SARS-CoV-2 natural immunity and its durability in the context of a pandemic in which new variants continuously emerge and challenge pre-existing immune responses in convalescents and vacinees. Our results serve as a warning that delays in vaccination programs could lead to an increase in re-infection rates of COVID-19 convalescents, caused by virus variants that escape humoral and cell-mediated immune responses. Furthermore, they reinforce the potential benefit of booster vaccination that is tuned to the active variants.

Competing Interest Statement

AS is currently a consultant for Gritstone, Flow Pharma, Arcturus, Epitogenesis, Oxfordimmunotech, Caprion and Avalia. La Jolla Institute for Immunology (AS and DW) has filed for patent protection for various aspects of T cell epitope and vaccine design work. Authors PGV, CMH, MGM, AELY, HB, ZAM, ZAD, AA, DA, AOS, AA, JG, CF, SO, EMM, DJL, GM, EJG, BAJR, DS, CKL, SGT, MRB, DW, RAB, SCB and BGB declare no conflict of interest.

Funding Statement

This work was funded by project grants from The Hospital Research Foundation and Women's and Children's Hospital Foundation, Adelaide, Australia. MGM is THRF Early Career Fellow. BGB is THRF Mid-Career Fellow. This project has been supported partly with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and Contract No. 75N9301900065 to A.S, D.W.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Study protocols were approved by the Central Adelaide Clinical Human Research Ethics Committee (#13050) and the Women's and Children's Health Network Human research ethics (protocol HREC/19/WCHN/65), Adelaide, Australia. All participants provided written informed consent in accordance with the Declaration of Helsinki and procedures were carried out following the approved guidelines.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 11, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection
Pablo Garcia-Valtanen, Christopher M. Hope, Makutiro G. Masavuli, Arthur Eng Lip Yeow, Harikrishnan Balachandran, Zelalem A. Mekonnen, Zahraa Al-Delfi, Arunasingam Abayasingam, David Agapiou, Alberto Ospina Stella, Anupriya Aggarwal, Jason Gummow, Catherine Ferguson, Stephanie O’Connor, Erin M. McCartney, David J. Lynn, Guy Maddern, Eric J Gowans, Benjamin AJ Reddi, David Shaw, Chuan Kok-Lim, Stuart G Turville, Michael R Beard, Daniela Weiskopf, Alessandro Sette, Rowena A. Bull, Simon C. Barry, Branka Grubor-Bauk
medRxiv 2021.11.08.21266035; doi: https://doi.org/10.1101/2021.11.08.21266035
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection
Pablo Garcia-Valtanen, Christopher M. Hope, Makutiro G. Masavuli, Arthur Eng Lip Yeow, Harikrishnan Balachandran, Zelalem A. Mekonnen, Zahraa Al-Delfi, Arunasingam Abayasingam, David Agapiou, Alberto Ospina Stella, Anupriya Aggarwal, Jason Gummow, Catherine Ferguson, Stephanie O’Connor, Erin M. McCartney, David J. Lynn, Guy Maddern, Eric J Gowans, Benjamin AJ Reddi, David Shaw, Chuan Kok-Lim, Stuart G Turville, Michael R Beard, Daniela Weiskopf, Alessandro Sette, Rowena A. Bull, Simon C. Barry, Branka Grubor-Bauk
medRxiv 2021.11.08.21266035; doi: https://doi.org/10.1101/2021.11.08.21266035

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (180)
  • Allergy and Immunology (435)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (423)
  • Epidemiology (9017)
  • Forensic Medicine (4)
  • Gastroenterology (422)
  • Genetic and Genomic Medicine (1963)
  • Geriatric Medicine (191)
  • Health Economics (405)
  • Health Informatics (1332)
  • Health Policy (662)
  • Health Systems and Quality Improvement (522)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10831)
  • Intensive Care and Critical Care Medicine (576)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (223)
  • Neurology (1842)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (357)
  • Occupational and Environmental Health (470)
  • Oncology (1006)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (184)
  • Pain Medicine (126)
  • Palliative Medicine (45)
  • Pathology (267)
  • Pediatrics (583)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1910)
  • Public and Global Health (4137)
  • Radiology and Imaging (678)
  • Rehabilitation Medicine and Physical Therapy (370)
  • Respiratory Medicine (551)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (110)
  • Urology (82)